Celcuity Inc. (CELC)
NASDAQ: CELC · Real-Time Price · USD
119.57
+6.01 (5.29%)
Apr 24, 2026, 1:48 PM EDT - Market open

Celcuity Earnings Call Transcripts

Fiscal Year 2026

  • Gedatolisib has shown unprecedented efficacy in second-line breast cancer, with strong early results in both wild-type and mutant populations. Commercial launch preparations are nearly complete, with a mid-July approval targeted, and international expansion is planned following key data readouts.

  • Three clinical trials are advancing for Gedatolisib, with key mutant data expected soon and strong confidence in regulatory timelines. Launch preparations are on track, targeting a large breast cancer market with a favorable safety profile and significant peak revenue potential.

  • Positive phase 3 data and NDA acceptance set the stage for a potential mid-2024 launch of gedatolisib, with robust commercial infrastructure nearly complete. The drug demonstrates unprecedented efficacy and tolerability, targeting a multi-billion dollar U.S. market opportunity.

Fiscal Year 2025

  • Achieved key milestones in 2025, including FDA priority review for gedatolisib and strong pivotal trial results. Net loss increased due to R&D and commercial investments, but cash reserves are expected to fund operations through 2027. Positive market feedback and a large addressable market support a strong outlook.

  • Gedatolisib, a pan-PI3K/mTOR inhibitor, is advancing through multiple phase III trials in HR-positive, HER2-negative breast cancer, showing strong efficacy and a favorable safety profile. The company is preparing for commercial launch, targeting a $6 billion market.

  • Major clinical and regulatory milestones were achieved, including positive phase III data for Gedatolisib and FDA acceptance for NDA submission. Financially, net loss widened year-over-year, but the balance sheet was strengthened with $455 million in cash and expanded debt capacity. Commercial launch preparations are advanced, with peak revenue potential estimated at $2.5–$3 billion.

  • Transformational progress includes strong clinical data for gedatolisib in breast and prostate cancer, robust regulatory and commercial preparations, and positive market feedback. Financial runway extends through 2027, with global regulatory strategies advancing.

  • Study Result

    The VIKTORIA-1 phase III trial showed that gedatolisib, as a triplet or doublet regimen, significantly improved progression-free survival and response rates in HR positive, HER2 negative advanced breast cancer patients with PIK3CA wild type disease, with a favorable safety profile and low discontinuation rates. NDA submission is expected this quarter.

  • Q2 2025 saw major clinical milestones, strong phase III data for gedatolisib, and a $287M capital raise. Net loss widened due to increased R&D, but cash runway now extends through 2027, supporting a potential launch in a $5B market.

  • Status Update

    Gedatolisib regimens in the VIKTORIA-1 Phase 3 trial showed unprecedented efficacy and safety for HR positive, HER2 negative, PIK3CA wild-type advanced breast cancer, with significant improvements in progression-free survival and favorable hazard ratios. Commercial launch preparations are underway, targeting a large unmet market.

  • The company is advancing therapies targeting the PAM pathway, with two phase III breast cancer studies and an early-phase prostate cancer study. Key data readouts are expected in Q3 and year-end, with NDA submission planned before year-end and a strong cash position supporting operations through 2026.

  • Gedatolisib, a multi-target PAM pathway inhibitor, is advancing through multiple late-stage trials in breast and prostate cancer, with key data readouts expected in Q3 and Q4. Early data show strong efficacy and safety, with differentiation from single-target drugs and potential for broad patient benefit.

  • Q1 2025 saw increased R&D and net losses as multiple late-stage clinical trials advanced, with key data readouts expected in 2025. Cash reserves are projected to fund operations through 2026, and a new endometrial cancer collaboration was announced.

  • Gedatolisib's comprehensive pathway inhibition and favorable safety profile differentiate it in breast cancer trials, with pivotal phase III data expected soon. A ≥3-month PFS improvement is the clinical benchmark, and strong financial resources support ongoing development.

  • Gedatolisib, a pan-PI3K/mTOR inhibitor, is advancing through pivotal trials in ER-positive breast cancer, showing strong efficacy and tolerability across patient subgroups. Upcoming data readouts and breakthrough designation position it for potential accelerated regulatory review.

  • Gedatolisib, a pan-PI3K mTOR inhibitor, has shown strong efficacy and tolerability in early studies, with upcoming phase III readouts expected to confirm its potential as a new standard in breast cancer treatment. Market adoption is supported by its broad applicability and manageable safety profile.

  • Gedatolisib (GetA) is advancing through multiple clinical programs, with phase III breast cancer data expected soon and a prostate cancer study underway. GetA offers comprehensive pathway inhibition and strong efficacy, targeting a large market with significant financial potential.

Fiscal Year 2024

Fiscal Year 2023

Fiscal Year 2022

Powered by